Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted to the city by Japan in the early 20th century show off their pink petals | ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo (TSE: 4568) to ...

Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an ...

The Delhi High Court is reviewing RHC Healthcare's challenge to the 'Fortis' trademark sale to Fortis Healthcare, alleging ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

Daiichi Sankyo has launched its oncolytic virus ... per dose, according to a Pharma Japan report. Approval was based on data from a single-arm phase 2 trial which showed that Delytact improved ...